Equities

Novacyt SA

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Novacyt SA

Actions
Health CareMedical Equipment and Services
  • Price (EUR)0.4005
  • Today's Change-0.009 / -2.20%
  • Shares traded2.85k
  • 1 Year change-33.03%
  • Beta0.1860
Data delayed at least 15 minutes, as of Feb 11 2026 08:34 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Novacyt SA is a France-based company providing biotechnological solutions. The Company develops and markets solutions dedicated to the field of liquid-based cytology and molecular biology. It provides diagnostic products used in oncology, microbiology, haematology, and serology testing. The Company develops secure automated cytology named NovaPrep Processor System. It offers a solution of cytological sampling to help in the detection of precancerous and cancerous lesions. It creates bottles specifically dedicated to the optimization of cell collection. The Company’s range of products includes Bottle Gyn and No Gyn Bottle.

  • Revenue in EUR (TTM)21.90m
  • Net income in EUR-31.83m
  • Incorporated2006
  • Employees234.00
  • Location
    Novacyt SA131 Boulevard Carnot, Le VesinetVELIZY VILLACOUBLAY 78110FranceFRA
  • Phone+33 139465104
  • Fax+33 130700532
  • Websitehttps://novacyt.com/fr
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Plant Advanced Technologies PAT SA941.74k318.01k9.42m16.0030.261.0010.6710.010.27760.27760.83778.38------58,858.75---1.51---1.96144.97128.3233.77-13.360.3156--0.2867--14.6110.441,081.17------
Oncodesign Precision Medicine Opm SA207.25k6.27m10.32m13.001.610.97351.5849.800.34570.34570.01140.57320.0119--0.263411,513.8936.11--54.21--6,372.89--3,026.21--0.92620.810.3859---80.69--10.89------
Predilife SA728.07k-3.80m12.58m27.00------17.28-0.9936-0.99360.1905-1.260.3919--3.6336,421.71-204.34-93.24---132.8098.1089.32-521.48-1,377.00---19.99----55.2084.82-0.9621---24.35--
Nfl Biosciences SAS0.00-3.15m14.93m4.00--4.36-----0.2779-0.27790.000.26990.00----0.00-66.86-75.08-91.01-121.22------------0.0088------44.44------
Poxel SA7.66m-13.66m15.16m5.00------1.98-0.2594-0.25940.1443-1.141.45--8.901,276,167.00-258.08-69.11---133.5152.0280.83-178.45-475.98---0.1862----234.98-24.2247.83------
Gensight Biologics SA194.00k-15.12m17.85m13.00------92.00-0.1293-0.12930.0016-0.2450.0174--10.7816,166.67-135.38-81.19---203.71-----7,793.81-868.76--------18.3916.4746.60---57.94--
Valbiotis SA472.00k-11.12m26.07m44.00--2.21--55.23-0.6994-0.69940.02970.49670.02061.574.8910,727.27-48.58-33.12-61.97-47.09-603.8119.74-2,354.87-464.772.93-74.380.3129---96.3013.97-36.06---2.02--
Novacyt SA21.90m-31.83m28.86m234.00--0.6156--1.32-0.451-0.49390.31050.66390.23542.345.2793,610.67-34.205.59-39.097.2963.3566.74-145.329.834.59-7.230.2114--84.8211.35-60.50--55.60--
genOway SA20.95m1.29m30.74m148.0016.271.147.601.470.14870.14872.422.120.5940.87973.69146,514.103.652.104.722.9194.9194.806.143.762.21--0.4407--10.0418.4616.79--15.88--
Theranexus SA0.00-2.94m33.11m10.00---------0.3641-0.36410.00-0.19230.00----0.00-66.82-44.47-148.89-50.85-----------37.712.90------74.15---56.53--
Fermentalg SA12.78m-11.54m37.42m63.00--1.32--2.93-0.1242-0.12420.13530.31560.24727.913.29199,734.40-17.09-18.10-21.17-20.5920.9425.51-69.14-147.661.83--0.2368--183.3243.528.99---4.91--
Eurofins Cerep SA40.46m7.15m93.82m207.0013.111.319.812.321,418.431,418.438,027.2414,234.140.49551.614.75195,445.808.7613.1210.2315.9085.6780.0217.6820.226.53--0.0046---8.205.46-6.3410.36----
Data as of Feb 11 2026. Currency figures normalised to Novacyt SA's reporting currency: Euro EUR
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.